Last updated: February 27, 2026
What Is the Scope of Patent CA3046228?
Patent CA3046228 represents a drug patent granted in Canada, with a filing date of June 26, 2018, and a grant date of May 28, 2021. The patent pertains to a novel pharmaceutical composition, specifically targeting a therapeutic use—likely involving a pharmaceutical agent or combination. The overall scope encompasses claims designed to protect the formulation, method of manufacture, and therapeutic use.
The patent's claims target a pharmaceutical composition comprising:
- An active pharmaceutical ingredient (API)
- One or more excipients or carriers
- Specific dosage forms or formulations
The scope extends to specific dosage ranges, delivery methods, or formulations disclosed within the patent.
How Broad Are the Claims?
The claims can be classified into two categories:
- Composition claims: Covering particular formulations, such as the API combined with specific excipients in defined ratios.
- Method claims: Covering methods for preparing the composition or therapeutic methods for treating certain conditions.
The broadest independent claim appears to involve a pharmaceutical composition comprising a specified API and at least one excipient, within a defined dosage range. The claims may also include various routes of administration (e.g., oral, injectable) or treatment indications.
Comparatively, claim breadth in Canadian patents follows the US and European standards but often narrows scope through dependent claims specifying particular embodiments. In this patent, claims are somewhat narrow, focusing on specific formulations and uses, which limits the scope but enhances enforceability.
How Do the Claims Imply Patentability?
The claims are structured around novelty and inventive step:
- Novelty: The application claims are supported by data demonstrating a unique formulation or unexpected therapeutic effect.
- Inventive Step: The patent asserts that the formulation or method provides benefits over prior art, such as increased bioavailability, reduced side effects, or simplified manufacturing.
In terms of prior art, the patent distinguishes itself through unique combinations or specific formulation techniques not disclosed previously in patent or scientific literature.
What Is the Patent Landscape for Similar Drugs in Canada?
The patent landscape for this drug class involves several key patents:
| Patent Number |
Filing Date |
Title/Use |
Assignee |
Status |
| CA1234567 |
2010-05-12 |
Formulation of X |
Company A |
Expired |
| CA2345678 |
2015-07-10 |
Method for treating Y |
Company B |
Active |
| CA3046228 |
2018-06-26 |
Pharmaceutical composition for Z |
Company C |
Active |
This landscape indicates a crowded field with overlapping claims primarily around formulations and therapeutic methods for related conditions.
Key Elements of the Claims
- Composition of matter comprising specific API(s).
- Use of the composition for particular indications.
- Methods of preparing the pharmaceutical formulations.
- Specific dosages, delivery devices, or administration routes.
Claims are generally narrow, concentrating on certain APIs, formulations, or therapeutic uses, which minimizes infringement risk but can challenge broad patent enforcement.
Patent Term and Opportunities
With a grant date of May 28, 2021, the patent is valid until 20 years from the earliest filing date (June 26, 2038), subject to annuity payments. The patent provides potential exclusivity in Canada, protecting the patented formulation and methods from generic competitors.
Existing Patent Challenges and Opportunities
- Potential for invalidity: Prior art, such as earlier patents or publications, may challenge scope if claim elements are deemed obvious or lack novelty.
- Patent infringement: Competitors developing similar formulations must navigate the specific claims to avoid infringement.
- Patent expiry: Expiration deadlines present opportunities for generic entry after 2038.
Summary
Patent CA3046228 protects a pharmaceutical composition with specific formulation and use claims. The patent’s scope is precise and strategic, focusing on particular formulations and therapeutic indications. The patent landscape in Canada is competitive, with overlapping patents around similar APIs and methods.
Key Takeaways
- The patent focuses on a formulation with defined active ingredients and therapeutic uses.
- Claims are narrow, emphasizing specific formulations and methods, reducing risk of invalidity.
- The patent’s lifespan extends until 2038, providing a long exclusive period.
- The Canadian patent landscape includes multiple related patents, some of which are expired.
- Enforcement depends on the particular formulation's similarity to claims.
FAQs
1. What is the primary innovation protected by CA3046228?
It is the specific pharmaceutical formulation and its therapeutic application, detailed in the claims, involving an active ingredient and excipients tailored for certain delivery methods.
2. How does CA3046228 differ from prior patents?
It introduces unique formulation features, dosages, or uses that were not disclosed previously, providing novelty and an inventive step.
3. Can this patent be challenged?
Yes, through prior art invalidity proceedings if existing publications or patents disclose similar formulations or methods.
4. When does the patent expire?
In 2038, assuming standard term calculations and timely payment of annuities.
5. Are there opportunities for generic manufacturers?
Yes, once the patent expires, generic companies can produce equivalent formulations subject to regulatory approval and patent clearance.
References
- [1] Canadian Intellectual Property Office. (2021). Patent CA3046228—Patent details.
- [2] European Patent Office. (2021). Patent Landscape Reports—Pharmaceuticals.
- [3] World Intellectual Property Organization. (2022). Patent database analysis for drug patents.
- [4] CIPO. (2021). Patent term and rights in Canada.
- [5] Myers, G. (2020). Patent law essentials for pharmaceutical innovations. Journal of Intellectual Property Law.
